SAN JOSE, June 29 — Anixa Biosciences has secured its first Korean patent for a breast cancer vaccine, a move that extends the company’s intellectual property protection in a key Asian market through 2040. The biotechnology firm, listed on the Nasdaq under the ticker ANIX, said the composition of matter patent from the Korean Ministry of… provides exclusive rights in South Korea. The patent covers the company’s breast cancer vaccine, a therapeutic approach aimed at preventing recurrence.
Officials noted the grant expands Anixa’s global IP estate into markets where breast cancer incidence rates are rising and where there is a greater concentration of younger patients. South Korea, data shows, fits that profile.
This is not Anixa’s first international patent win. The company has been building a portfolio of protections across multiple jurisdictions, but the Korean grant marks a specific milestone for the Asian region. The patent runs through 2040, giving the firm a long runway for commercial development in a country with a sophisticated biotechnology sector and growing healthcare investment.
For Central Asian markets, the development signals something broader. Kazakhstan, Uzbekistan, and other regional economies are watching how biotech firms protect their assets in emerging markets.
Anixa’s strategy of securing patent protection before clinical rollout is a model that resonates with investors who track intellectual property as a leading indicator of market access. The company focuses on the treatment and prevention of cancer, with this vaccine targeting a specific form of the disease. Breast cancer remains one of the most common cancers globally, and incidence rates in younger populations have been a concern for public health officials in several Asian countries.
The Korean patent, officials noted, aligns with Anixa’s goal of addressing that demographic shift. Anixa did not disclose the exact number of patents it now holds globally, but the company said the Korean grant is part of a growing international IP estate. The firm’s approach combines a novel antigen target with a delivery platform designed to train the immune system to attack cancer cells.
Clinical data on the vaccine’s efficacy has been reported in earlier studies, though the company did not release new trial results alongside the patent announcement. Investors have been watching Anixa’s patent progress closely.
The biotech sector often values companies on the strength of their IP portfolios, and a patent through 2040 provides a clear timeline for potential licensing deals or partnerships. South Korea’s pharmaceutical market, with its advanced manufacturing capabilities and regulatory alignment with global standards, makes it a logical early target for patent protection. The company, based in San Jose, California, made the announcement on June 29.
The patent grant does not immediately change Anixa’s revenue outlook — the vaccine is still in development — but it removes a layer of uncertainty for those betting on its commercial future. For now, the focus remains on clinical progress and expanding the patent map. Consult your doctor for medical advice.
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Anixa Biosciences Gets First Korean Patent for Breast Cancer Vaccine”, “description”: “SAN JOSE, June 29 — Anixa Biosciences has secured its first Korean patent for a breast cancer vaccine, a move that extends the company’s intellectual…”, “datePublished”: “2026-06-29 12:45:00T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “Aibek Nurlan”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.infopulsetoday.com/”}}
